Onyx TruStarTM DES

Designed to
lead the way

Onyx TruStarTM DES introduces an enhanced delivery system§ designed to take the acute performance of Resolute Onyx™ DES even further.​
2

Enhanced delivery system​

onyx
asset
onyx graph

Onyx TruStarTM DES...

16
75
29

Product features​

Onyx TruStarTM DES builds off the legacy of Resolute Onyx DES, featuring the​ same stent design differentiators that provide the conformability,3 visibility,4​ fast healing,5 and size matrix you’ve come to rely on.

Increased conformability: single-wire design

In comparison to laser-cut drug-eluting stents, only Medtronic DES are made from  a single wire to enable a fluid  range of motion and the conformability needed for superior strut apposition.3​

conformability

Increased visibility and radial strength: platinum-iridium core ​​

The platinum-iridium core within Onyx TruStar™ DES is more visible4 than competitive DES, while still enabling greater radial strength4 with thin struts.​

platinum

Promotes faster healing5: BioLinx™ biocompatible polymer

Illustration of the BioLinx polymer — part of Onyx Frontier DES

The zotarolimus drug inhibits neointimal growth,6 while the BioLinx biocompatible polymer — the only polymer specifically designed for a DES — promotes fast healing and enables 1-month DAPT in high bleeding risk patients.​

Broad diameter range​

Only Medtronic offers DES in 2.0 mm to 5.0 mm sizes, with overexpansion capabilities up to 6.0 mm,# to treat the broadest range of coronary vessel diameters.

Platform Stent diameter (mm) Stent length

MSID#(mm)

Small vessels

2.00

2.25

2.50

8

8

8

12

12

12

15

15

15

18

18

18

22

22

22

26

26

26

30

30

30

--

34

34

--

38

38

3.50

3.50

3.50

Medium vessels

2.75

3.00

8

8

12

12

15

15

18

18

22

22

26

26

30

30

34

34

38

38

4.00

4.00

Large vessels

3.50

4.00

8

8

12

12

15

15

18

18

22

22

26

26

30

30

34

34

38

38

5.00

5.00

Extra-large vessels

4.50

5.00

-

-

12

12

15

15

18

18

22

22

26

26

30

30

--

--

--

--

6.00

6.00

Additional resources

product info
tech spec
order info

Complex PCI

Optimised for complex PCI

An exclusive set of design features and clinical data help ensure you have a reliable DES, even for your most challenging cases:

Left main and other extra-large vessel PCI (4.50–⁠5.00 mm sizes)

  • Specifically designed with additional crowns and thicker struts to provide the radial strength needed for extra-large vessels7
  • Maintain a low profile,7 allowing for 5 F compatibility
  • 4.50–5.00 mm expand up to 6.00 mm# while maintaining structural integrity7
Onyx Frontier DES expanded to 6.0 mm next to medical illustration of Onyx in the body under fluoro

Bifurcation PCI

  • Other DES feature irregular cell shapes which may obstruct wire or catheter advancement through the cell’s opening.7
  • Round struts create a smooth passage when accessing the side branch while lowering the propensity to catch.7
Illustration of Onyx Frontier DES inside the body with a catheter running through it and out of it

Rounded struts

Illustration of Medtronic DES rounded struts

Onyx TruStarTM DES

Square struts

Illustration of square struts used by competitive coronary stents

1. SYNERGYTM* DES
2. XIENCETM* DES

Extra-small vessel PCI (2.00–2.50 mm sizes)

  • 2.00 mm offers the lowest crossing profile of any DES7
  • Demonstrated 2% target lesion revascularisation and 0% stent thrombosis at one year in a complex, small-vessel population8
  • 2.00–2.50 mm expand up to 3.50 mm# with minimal foreshortening for tapered and extra-small vessels7
Onyx Frontier DES 3.5 mm maximum stent inner diameter next to medical illustration of Onyx in the body under fluoro

HBR patients who may require 1-month dual antiplatelet therapy (DAPT)

  • Up to 40% of patients are at high bleeding risk (HBR) while 20% may need to interrupt or discontinue DAPT earlier than prescribed.9,10
  • Onyx TruStar™ DES is conformable, providing superior strut apposition12 while the BioLinx™ biocompatible polymer provides superior thromboresistance.11 When combined, fast healing occurred,5 providing the option to shorten DAPT duration to 1-month in HBR patients.
  • Based on the results from the Onyx ONE Global Trial, Onyx TruStar™ DES is indicated for 1-month DAPT in HBR patients, including those unable to tolerate long-term DAPT.13
Illustration of the Onyx Frontier DES shown inside the artery

Let's get in touch!

Looking for more information, product updates, clinical data, news and events on Onyx TruStarTM DES?​ Simply complete below contact form.
contact us frontier

*Indicates Required Field

Your information will be processed and protected in accordance with our privacy statement

Selecting “no” to marketing emails above will not affect your other email selections, and a Medtronic representative will still reach out via email, if selected. Your personal data will used to manage your relationship with Medtronic, and, if you consent, to provide you with relevant email updates based on your user preferences. You can opt-out of receiving such emails at any time by clicking the unsubscribe link in the relevant email. Medtronic may use pixels and other technologies in emails to gather statistics around email opening and clicks, to help us improve our communications and to provide you with relevant content. For more information, see the Medtronic privacy notice.

You can always change your preferences or update your personal details by visiting the Preference center.

See the Preference center

The content of this website is exclusively reserved for Healthcare Professionals in countries with applicable health authority product registrations, except those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011, article 34.

Onyx TruStar DES is exclusively available in Austria, Denmark, Finland, Germany, Greece, Iceland, Israel, Netherlands, Norway and Sweden.​

References

§ Stent delivery system updates were implemented on the 2.0–4.0 mm Onyx​ TruStar DES diameter.​

# Stents should not be expanded to a diameter beyond the maximum labeled diameter listed per the IFU. Post-dilation required for overexpansion​.

‡ Onyx TruStar DES has the same stent platform, with platinum-iridium core, as Resolute Onyx DES. ​

1 Based on bench test data on file at Medtronic, D00339634, Rev C. May not be indicative of clinical performance. N = 7 DES of each tested: Onyx TruStar DES, Resolute Onyx DES, Orsiro®* DES, XIENCE Sierra™* DES, SYNERGY™* DES.​

2 Based on bench test data on file at Medtronic, D00624519, Rev A. Compared to Resolute Onyx DES. May not be indicative of clinical performance.​

3 Third-party modeling and analysis, Mortier MDT-ON14-report-curved-v10-20150220_Onyx_Synergy.pdf. May not be indicative of clinical performance. Evaluated the following stent platforms: Resolute Onyx DES, SYNERGY™* DES, and XIENCE Alpine™* DES (Multi-Link 8 platform).​

4 Based on bench test data on file at Medtronic, CO10276086 University of Budapest Visibility Testing, v1. May not be indicative of clinical performance.​

5 Roleder T, Kedhi E, Berta B, et al. Short-term stent coverage of second-generation zotarolimus-eluting durable polymer stents: Onyx one-month optical coherence tomography study. Adv Interv Cardiol. 2019;15(2):143-150.​

6 Yeh RW, Silber S, Chen L, et al. 5-Year Safety and Efficacy of Resolute Zotarolimus-Eluting Stent: The RESOLUTE Global Clinical Trial Program. JACC Cardiovasc Interv. February 13, 2017;10(3):247-254.​

7 Based on bench test data on file at Medtronic, D00339634, Rev C. May not be indicative of clinical performance. N=5 of each DES tested.

8 Cuellas C, et al. Use of a Zotarolimus-eluting stent for small vessel disease (DISCO 9 Study). Presented at PCR 2021.​

9 Windecker S. Stent Selection for 1-3 Month DAPT: Current Evidence Ongoing Studies. Presented at TCT 2018; San Diego, CA.​

10 Silber S, Kirtane AJ, Belardi JA, et al. Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. Eur Heart J. August 1, 2014;35(29):1949-1956.​

11Jinnouchi H, Sato Y, Cheng Q, et al. Thromboresistance and endothelial healing in polymer-coated versus polymer-free drug-eluting stents: Implications for short-term dual anti-platelet therapy. Int J Cardiol. March 15, 2021;327:52-57.​

12 Third-party modeling and analysis. [Mortier MDT-ON14-report-curved-v10-20150220_Onyx_Synergy] Data may not be indicative of clinical performance. Evaluated the following stent platforms: Resolute Onyx DES, Multi-Link 8™️* BMS, SYNERGY™️* DES, XIENCE Alpine™️* DES, and Multi-Link 8 platform.

13 Windecker S, et al. N Engl J Med. 2020;382:1208-1218.

See the device manual for detailed information regarding the instructions for use, the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events. For further information, contact your local Medtronic representative and/or consult the Medtronic website at www.medtronic.eu.

For applicable products, consult instructions for use on manuals.medtronic.com. Manuals can be viewed using a current version of any major internet browser. For best results, use Adobe Acrobat® Reader with the browser.

CE mark 2797